These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 32747413)

  • 41. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
    Voutsadakis IA
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Brown ZJ; Gregory S; Hewitt DB; Iacono S; Choe J; Labiner HE; Pawlik TM
    Surg Oncol; 2022 Jun; 42():101748. PubMed ID: 35395582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.
    Piñero F; Silva M; Iavarone M
    World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together.
    D'Alessio A; Cammarota A; Prete MG; Pressiani T; Rimassa L
    Curr Opin Oncol; 2021 Jul; 33(4):386-394. PubMed ID: 33867478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
    Chan LL; Chan SL
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
    Bresnahan E; Lindblad KE; Ruiz de Galarreta M; Lujambio A
    Clin Cancer Res; 2020 Oct; 26(20):5276-5286. PubMed ID: 32327473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
    Schulte N; Li M; Zhan T; Dreikhausen L; Sollors J; Antoni C; Diehl S; Schoenberg SO; Rahbari N; Reissfelder C; Giordano FA; Ebert MP; Teufel A
    Z Gastroenterol; 2020 Aug; 58(8):773-777. PubMed ID: 32785913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].
    Li ZC; Ren ZG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):600-603. PubMed ID: 34225439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
    Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
    Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.